Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. [electronic resource]
Producer: 20060316Description: 307-11 p. digitalISSN:- 1558-3597
- Abciximab
- Angina, Unstable -- blood
- Antibodies, Monoclonal -- therapeutic use
- Biomarkers -- blood
- C-Reactive Protein -- analysis
- CD40 Ligand -- blood
- Creatine Kinase -- blood
- Creatine Kinase, MB Form -- blood
- Growth Substances -- blood
- Humans
- Immunoglobulin Fab Fragments -- therapeutic use
- Multivariate Analysis
- Myocardial Infarction -- blood
- Myocardial Ischemia -- blood
- Placenta Growth Factor
- Platelet Aggregation Inhibitors -- therapeutic use
- Platelet Glycoprotein GPIIb-IIIa Complex -- antagonists & inhibitors
- Predictive Value of Tests
- Pregnancy Proteins -- blood
- Prognosis
- Proportional Hazards Models
- Randomized Controlled Trials as Topic
- Risk Assessment
- Troponin T -- blood
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.